Muhammad Adnan

Array ( [id] => 17674115 [patent_doc_number] => 20220187282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => CARDIOMYOCYTE PROLIFERATION [patent_app_type] => utility [patent_app_number] => 17/440081 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17440081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16511550 [patent_doc_number] => 20200390807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => COMPOSITION AND METHOD FOR TARGETING NATURAL KILLER CELLS IN IMMUNOTHERAPY TO OVERCOME TUMOR SUPPRESSION WITH MANGANESE DIOXIDE NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 16/971425 [patent_app_country] => US [patent_app_date] => 2019-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16971425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003591 [patent_doc_number] => 20220362357 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/271824 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27614 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17274748 [patent_doc_number] => 20210380946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => REDUCED INTENSITY CONDITIONING WITH MELPHALAN [patent_app_type] => utility [patent_app_number] => 17/289135 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14930437 [patent_doc_number] => 20190300856 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => Messenger RNA based expression of opsins and reporter proteins for electrophysiologic characterization of in vitro neurons and cardiomyocytes [patent_app_type] => utility [patent_app_number] => 15/998754 [patent_app_country] => US [patent_app_date] => 2018-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15998754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355378 [patent_doc_number] => 20220016174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => FOETAL MESENCHYMAL STEM CELL COMPOSITION OF ALLOGENIC ORGIN, TREATMENT METHOD AND USE THEREOF IN MASTITIS IN MILK-PRODUCING ANIMALS, INCLUDING CATTLE [patent_app_type] => utility [patent_app_number] => 17/251954 [patent_app_country] => US [patent_app_date] => 2018-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15119 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17251954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12178932 [patent_doc_number] => 20180037869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'CELL THERAPEUTIC AGENT FOR CANCER TREATMENT AND COMBINATION THERAPY WITH SAME' [patent_app_type] => utility [patent_app_number] => 15/554849 [patent_app_country] => US [patent_app_date] => 2016-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 12128 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15554849 [rel_patent_id] =>[rel_patent_doc_number] =>)